ABSTRACT
Purpose: This study reported 11 cases of new‐onset acute uveitis following coronavirus disease 2019 (COVID‐19) vaccination. Methods: This retrospective observational case study included 11 eyes from 11 patients with acute uveitis after COVID‐19 vaccination. We only included patients with new‐onset uveitis. Patients' medical records from January 2021 to January 2022 were reviewed. Results: The mean age of the participants was 51.81 years, and all patients demonstrated anterior chamber reaction with keratic precipitates in the affected eye. The mean duration between vaccination and uveitis was 8.27 days. Seven patients developed uveitis after receiving the second vaccination, and four developed uveitis after receiving the third vaccination. Five patients showed posterior synechiae and three patients showed hypopyon. After treatment with topical 1% prednisolone acetate eye drops and systemic prednisolone, inflammation was adequately controlled and quickly resolved. Conclusions: COVID‐19 vaccination with messenger RNA and viral vector vaccines may cause acute anterior uveitis. Although initially severe, the patients' uveitis responded well to steroid therapy, without visual impairment. References 1. Aslam S, Goldstein DR, Vos R, et al. COVID‐19 vaccination in our transplant recipients: The time is now. J Heart Lung Transplant 2021;40:169–171. 2. Calina AO, Docea D, Petrakis D, et al. Towards effective COVID19 vaccines: updates, perspectives and challenges (review). Int J Mol Med 2020;46: 3–16. 3. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV‐19 vaccine administered in a prime‐boost regimen in young and old adults (COV002): a single‐blind, randomized, controlled, phase 2/3 trial. Lancet 2021, 396: 1979–93.